Press release
RNA - based Therapeutics and Vaccines Market 2016 – Global Industry Key Growth Factor Analysis and Research Study till 2024
Ongoing research and development activities for the development of advanced biological drugs have widened the scope of therapeutic targets for a verity of diseases. This includes numerous RNA-based therapeutics under clinical trials for conditions such as genetic diseases and infectious diseases such as HIV-AIDS, as RNA controls human gene expression.
Request for Report TOC @ https://www.persistencemarketresearch.com/toc/12868
RNA-based therapeutics is mainly classified by its activity mechanism, and include inhibitors of mRNA translation (antisense), catalytically active RNA molecules (ribozymes), the agents of RNA interference (RNAi), and RNAs that bind protein and other molecular ligands (aptamers). RNAi was discovered in 1990 and termed post-transcriptional gene silencing as it works by turning off or silencing gene expression. Currently here are around 700 nucleic acid-based (DNA and RNA) therapeutics in the pipeline and around 60% of that are in preclinical development. Among these, 60% of pipeline products, 30% therapeutics are for the treatment of oncology. This technology has appeared to be dominant in the RNA-based therapeutics and vaccines market. Other technology such as RNA antisense, involves RNA strand synthesis, which binds to a specific mRNA in order to prevent translation. However, the issue of toxicity and drug delivery associated with RNA-based therapies is a significant challenge for commercialization. However, several new technologies have emerged to overcome these challenges, which will lead to the promising future of RNA-based therapeutics.
The RNA-based therapeutics and vaccines market is be categorized based on technology, application, disease indications and end users. The technology segment is further segmented into mRNA, siRNA, miRNA and RNA interference. The application segment is further segmented into, diseases diagnosis, therapeutics, research & development, and drug discovery. Based on disease indication, the market is segmented into, cardiovascular, infectious, respiratory, neurodegenerative, genetic and renal diseases. In this market, infectious disease segment is expected to witness highest growth rate during the forecast period due to growing incidence of AIDS and Hepatitis B. Based on the end user; the market is segmented into the pharmaceutical industry, agriculture industry, clinical research organization and other. Presently, research institutes primarily utilize RNA technology for the development of RNA drugs, thereby accounting for the largest market share.
On the basis of region presence, RNA-based therapeutics and vaccines market is segmented into five key regions: North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. Currently, North America dominates the global market for RNA-based therapeutics and vaccines followed by Europe, owing to the high adoption of advanced technologies for drug discovery and development. Further, the rising number of cancer patients and increasing diagnosis rate of infectious diseases and increase in the prevalence of the neurodegenerative and cardiovascular disease is expected to fuel the RNA-based therapeutics and vaccines market. Moreover, a substantial investment in research and development, availability of high-end infrastructure for the development and growing government support of RNA are few of the factors responsible for the market growth. RNA-based therapeutics and vaccines market in Asia-Pacific and the Middle East and Africa is expected to register high growth due to developing healthcare infrastructure and high prevalence of infectious diseases
Request for Report Sample @ https://www.persistencemarketresearch.com/samples/12868
Some of the major market players in RNA-based therapeutics and vaccines market globally include Sanofi S.A, Atlantic Pharmaceuticals Inc., GlaxoSmithKline plc, Novartis AG, AstraZeneca plc., Isis Pharmaceuticals, Bristol-Myers Squibb, Alnylam Pharmaceuticals Inc. Quark Pharmaceuticals, Inc, Silence Therapeutics PLC. The market is currently witnessing a number of strategic collaboration and partnership activities by pharmaceutical and biotechnology companies.
About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.
Contact Us
Persistence Market Research
305 Broadway,7th Floor
New York City, NY 10007
United States
Tel: +1-646-568-7751
Tollfree: +1 800-961-0353
Email: sales@persistencemarketresearch.com
Website: https://www.persistencemarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release RNA - based Therapeutics and Vaccines Market 2016 – Global Industry Key Growth Factor Analysis and Research Study till 2024 here
News-ID: 777877 • Views: …
More Releases from Persistence Market Research
Frozen Foods Market Heats Up with Innovation and Growing Consumer Demand
Market Overview:
The frozen foods market consists of a wide range of products, including frozen fruits and vegetables, meat and seafood, ready-to-eat meals, and desserts. These products are preserved through freezing to maintain freshness and quality for an extended period.
Market Size and Growth:
The global market for frozen foods is forecasted to be of valuation US$ 281.0 Billion in the year 2022 which is expanding at a value CAGR of 5.1% and…
The Global Graphene Market's Striking Growth and Innovative Applications
Introduction
Graphene, a single layer of carbon atoms arranged in a hexagonal lattice, has gained global recognition for its extraordinary properties, such as exceptional electrical and thermal conductivity, mechanical strength, and flexibility. Since its isolation in 2004 by Andre Geim and Konstantin Novoselov, graphene has sparked considerable interest in both scientific and industrial communities. This report explores the current state of the graphene market and its potential growth opportunities.
Get Access To…
Business Opportunities in Cyber Security Mesh Market : Top Countries Data Analys …
Market Overview:
The projected global market size for cyber security mesh is expected to reach $8.8 billion by the year 2033, with an estimated valuation of $1.2 billion by 2023. This market is poised to experience a compound annual growth rate (CAGR) of 21.7% from 2023 to 2033.
The global Cyber Security Mesh market is poised for significant growth as organizations worldwide grapple with the escalating threat landscape. Cybersecurity has become an…
Synthetic Beta-Carotene Market To Boost Incredible Growth: 2033, Share Valuation …
Key market trends included a shift towards natural and plant-based ingredients, as consumers sought cleaner labels and healthier options. This drove the demand for naturally sourced beta-carotene, but synthetic beta-carotene still had its place due to its cost-effectiveness and consistency in production. The market was also influenced by regulatory changes and evolving dietary preferences, which affected the application and formulation of synthetic beta-carotene in various products.
To obtain the latest market…
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand.
Browse 156 Market Data Tables and 112 Figures spread through 175…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited.
Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring…
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year.
Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved…
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018!
Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led…
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion.
One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and…
